Answers are grounded in this paper and cite their sources.
In vitro study reveals potent antimicrobial activity of novel thiazolopyridine–sulfonamide hybrids, highlighting their potential as dihydrofolate reductase inhibitors.
A series of thiazolo[5,4-b]pyridine–based sulfonamide derivatives was designed and synthesized using a cyanoacetyl sulfonamide intermediate to access various heterocyclic frameworks. Their antimicrobial activity was evaluated in vitro against Staphylococcus aureus , Escherichia coli , and Candida albicans using agar diffusion and minimum inhibitory concentration (MIC) determination. Several compounds exhibited potent antibacterial activity with MIC values ranging from 3.125 to 12.5 μg/mL, where compounds 10 , 16 , and 21 showed broad-spectrum activity comparable to or superior to reference drugs. Structure–activity relationship (SAR) analysis indicated that electron-withdrawing and aromatic substituents enhanced antimicrobial potency. Molecular docking studies against dihydrofolate reductase (DHFR, PDB ID: 2W9S) supported the experimental results, revealing favorable binding interactions and high affinity of the most active compounds. These findings suggest that thiazolo[5,4-b]pyridine–sulfonamide hybrids represent promising scaffolds for the development of new antimicrobial agents.
No takes yet. Share an insight, caveat, or question.
Noof A. Alenazi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: